查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
乳癌液体活检市场：成长、未来展望和竞争分析（2024-2032 年）
市场调查报告书
商品编码
1642607

乳癌液体活检市场：成长、未来展望和竞争分析（2024-2032 年）

Breast Cancer Liquid Biopsy Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
出版日期: | 出版商: Acute Market Reports | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

预计 2024-2032 年预测期内乳癌液体活检市场将以 22.7% 的复合年增长率成长。乳癌液体活检市场是一个快速发展的领域，利用非侵入性液体活检透过血液样本检测和监测乳癌。该方法比传统的组织活检有了显着的进步，可以即时洞察肿瘤动态并制定个人化的治疗策略。该技术具有彻底改变癌症检测和管理的潜力，并处于肿瘤学研究和临床应用的前沿。

促进因素

基因组技术的进展

基因组定序和分析技术的进步是推动乳癌液体活检市场发展的关键因素。下一代定序（NGS）和聚合酶链反应（PCR）技术的日益复杂化，为乳癌的遗传基础提供了更深入的瞭解，并且可以检测血液中微量的肿瘤 DNA。这些进展不仅提高了液体活检的敏感性和特异性，而且拓宽了其潜在的应用，包括早期检测、预后预测以及治疗反应和抗药性的监测。基因组技术的持续改进促进了液体活检在临床实践中的广泛应用。

对非侵入性手术的需求不断增加

患者和医疗保健提供者对非侵入性诊断程序的偏好日益增加也是乳癌液体活检市场发展的主要驱动力。传统的组织活检虽然有效，但具有侵入性并且常常引起不适和潜在的併发症。相较之下，液体活检提供了一种微创的替代方法，只需抽血即可完成，从而减轻患者的压力和风险。这种患者友善的方法对于监测肿瘤进展或治疗反应所需的重复检测特别有利，使得液体活检成为持续疾病管理的一个有吸引力的选择。

乳癌发生率上升

全球乳癌发生率的上升极大地刺激了对有效诊断和监测工具的需求，从而促进了液体活检市场的发展。乳癌是世界上最常见的癌症之一，迫切需要先进的诊断技术，以便更早发现并改善患者的治疗效果。液体活检透过提供一种可以从血液样本中检测出早期癌症的工具来满足这一需求，从而促进及时干预和个人化治疗计划。全球范围内乳癌发生率的不断上升是推动液体活检解决方案开发和应用的主要驱动力。

抑制因素

监管和报销课题

儘管乳癌液体活检市场具有潜力且正在成长，但它面临着监管和报销课题等方面的重大限制。由于液体活检测试新颖而复杂，获得 FDA 等机构监管批准的障碍很高。此外，缺乏使用和解释液体活检的标准化指南也增加了监管课题。在报销方面，液体活检的保险覆盖范围有限以及报销政策不明确可能会阻碍医疗保健提供者采用这项技术。这些监管和报销问题构成了巨大的障碍，阻碍了市场的成长和采用。

按生物标誌物细分的市场

乳癌液体切片市场按生物标记细分，例如循环肿瘤细胞（CTC）、无细胞 DNA（cfDNA）、外泌体和其他生物标记。其中，cfDNA因其在检测和监测微小残留疾病和治疗抗药性方面具有很高的临床实用性，在收入方面处于领先地位。cfDNA 在临床实践中受到青睐，因为它可以快速、非侵入性地洞察肿瘤遗传学。此外，由于定序技术的不断进步和临床应用的不断增加，预计 cfDNA 在预测期内将呈现最高的复合年增长率 (CAGR)。然而，CTC 也发挥着重要作用，特别是在瞭解转移过程方面，但由于其分离和分析相关的技术课题，它们仅占市场的一小部分。外泌体越来越受欢迎，因为它们提供全面的分子讯息，可以深入瞭解肿瘤行为和治疗反应。其他生物标誌物，包括蛋白质和代谢物，正在接受研究，并显示出良好的前景，因为它们可以补充现有的生物标记物，从而实现更详细的疾病分析和治疗效果评估。

按产品/服务细分市场

乳癌液体活检市场按产品/服务细分为试剂盒/试剂和服务。试剂盒和试剂占据了主要收入，因为它们是液体活检测试的基础。该行业受益于与液体活检相关的频繁消费和定期购买，这些测试涉及患者治疗过程中的多个测试阶段。此外，旨在提高准确性和效率的试剂和试剂盒的不断创新也支持了高收入。同时，服务业预计将以最高的复合年增长率成长。这种成长是由人们对包括测试交付、数据分析和可操作见解在内的综合服务产品的日益增长的偏好所推动的。专业诊断服务的兴起以及实验室能力的扩大以适应先进的液体活检技术，对这一领域的成长做出了重大贡献。

地理趋势

乳癌液体活检市场呈现出动态的地理趋势，由于先进的医疗保健基础设施、对癌症筛检的高度认识以及主要市场参与者的存在，北美目前在收入方面处于领先地位。然而，由于医疗支出增加、患者意识提高和医疗设施改善，亚太地区预计将在 2024 年至 2032 年期间呈现最高的复合年增长率 (CAGR)。中国、印度等国家乳癌发生率不断上升，加上医疗技术投入不断增加，推动了该地区乳癌的快速成长。由于强大的癌症诊断监管框架和高昂的医疗支出，欧洲也占了相当大的市场占有率。

竞争趋势

乳癌液体切片市场正在迎来一些知名企业，例如 Datar Cancer Genetics、Epic Sciences、F. Hoffmann-La Roche、Genes2me、Illumina、Menarini Silicon Biosystems、Myriad Genetics、OncoDNA、QIAGEN、Sysmex、System Biosciences、Myriad Genetics、OncoDNA、QIAGEN、Sysmex、System Biosciences、Thermoist Fisher Scisciences。这些公司采取了各种策略来加强其市场地位并扩大其收入来源。2022年，这些公司实现了可观的收入，反映了其市场主导地位和创新能力。预计这些公司在 2024-2032 年预测期内的策略将集中在技术创新、併购和地理扩张。例如，许多公司正在透过整合先进的基因组技术来增强其产品线，以提高液体活检的准确性和可靠性。对于寻求全球扩张的公司来说，合作伙伴关係和协作也至关重要，尤其是进入亚太地区和拉丁美洲尚未开发的市场。此外，投资研发是这些公司的关键策略，旨在率先发现新的生物标记并提高现有液体活检技术的灵敏度。这些策略努力符合全球整体市场扩张趋势，预计将在未来几年推动这些公司的持续成长和竞争优势。

目录

第1章 前言

  • 分析内容
    • 分析目的
    • 目标受众
    • 主要产品
  • 市场细分
  • 分析方法
    • 第一阶段：二次研究
    • 第二阶段：初步调查
    • 第三阶段：专家评审
    • 先决条件
    • 采取的方法

第 2 章 执行摘要

第 3 章 乳癌液体切片市场竞争分析

  • 主要厂商市场定位
  • 供应商采取的策略
  • 主要产业战略

第 4 章 乳癌液体切片市场：宏观分析与市场动态

  • 介绍
  • 全球乳癌液体活检市场（价值，2022-2032 年）
  • 市场动态
    • 市场驱动力
    • 市场制约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析
  • 波特的五力模型
    • 供应商实力
    • 购买力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手之间的竞争
  • PESTEL 分析
    • 政局
    • 经济情况
    • 技术情况
    • 法律状况
    • 社会局势

第 5 章 乳癌液体切片市场（依生物标记划分） (2022-2032)

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 市场细分
    • 循环肿瘤细胞 (CTC)
    • 游离 DNA（cfDNA）
    • 外泌体
    • 其他生物标誌物

第 6 章 乳癌液体切片市场（按产品和服务划分） (2022-2032)

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 市场细分
    • 试剂盒/试剂
    • 服务

第 7 章 乳癌液体切片市场按样本类型划分（2022-2032 年）

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 市场细分
    • 血液
    • 尿
    • 其他类型的样品

第 8 章 乳癌液体切片市场依最终用途划分（2022-2032 年）

  • 市场概况
  • 成长/利润分析：2023 年与 2032 年
  • 市场细分
    • 医院
    • 癌症研究中心
    • 诊断中心
    • 学术研究所

第 9 章 北美乳癌液体切片市场（2022-2032）

  • 市场概况
  • 乳癌液体活检市场（按生物标记） (2022-2032)
  • 乳癌液体活检市场（按产品和服务划分） (2022-2032)
  • 乳癌液体活检市场（按样本类型） (2022-2032)
  • 乳癌液体活检市场按最终用途划分（2022-2032 年）
  • 乳癌液体活检市场（按地区） (2022-2032)
    • 北美
      • 美国
      • 加拿大
      • 其他北美

第 10 章 英国和欧盟乳癌液体活检市场（2022-2032）

  • 市场概况
  • 乳癌液体活检市场（按生物标记） (2022-2032)
  • 乳癌液体活检市场（按产品和服务划分） (2022-2032)
  • 乳癌液体活检市场（按样本类型） (2022-2032)
  • 乳癌液体活检市场按最终用途划分（2022-2032 年）
  • 乳癌液体活检市场（按地区） (2022-2032)
    • 英国/欧盟国家
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 欧洲其他地区

第 11 章 亚太地区乳癌液体切片市场（2022-2032）

  • 市场概况
  • 乳癌液体活检市场（按生物标记） (2022-2032)
  • 乳癌液体活检市场（按产品和服务划分） (2022-2032)
  • 乳癌液体活检市场（按样本类型） (2022-2032)
  • 乳癌液体活检市场按最终用途划分（2022-2032 年）
  • 乳癌液体活检市场（按地区） (2022-2032)
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 亚太其他地区

第 12 章 拉丁美洲乳癌液体切片市场（2022-2032）

  • 市场概况
  • 乳癌液体活检市场（按生物标记） (2022-2032)
  • 乳癌液体活检市场（按产品和服务划分） (2022-2032)
  • 乳癌液体活检市场（按样本类型） (2022-2032)
  • 乳癌液体活检市场按最终用途划分（2022-2032 年）
  • 乳癌液体活检市场（按地区） (2022-2032)
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第 13 章 中东和非洲乳癌液体切片市场（2022-2032）

  • 市场概况
  • 乳癌液体活检市场（按生物标记） (2022-2032)
  • 乳癌液体活检市场（按产品和服务划分） (2022-2032)
  • 乳癌液体活检市场（按样本类型） (2022-2032)
  • 乳癌液体活检市场按最终用途划分（2022-2032 年）
  • 乳癌液体活检市场（按地区） (2022-2032)
    • 中东/非洲
      • 海湾合作委员会
      • 非洲
      • 其他中东/非洲地区

第14章 公司简介

  • Datar Cancer Genetics
  • Epic Sciences
  • F. Hoffmann-La Roche
  • Genes2me
  • Illumina
  • Menarini Silicon Biosystems
  • Myriad Genetics
  • OncoDNA
  • QIAGEN
  • Sysmex
  • System Biosciences
  • Thermo Fisher Scientific
  • Twist Bioscience
  • 其他主要公司
Product Code: 140825-11-24

The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies. The technology's potential to revolutionize cancer detection and management has positioned it at the forefront of oncology research and clinical application.

Drivers

Advancements in Genomic Technologies

Technological advancements in genomic sequencing and analysis have been pivotal in driving the breast cancer liquid biopsy market. As next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have become more sophisticated, they offer deeper insights into the genetic basis of breast cancer, enabling the detection of minute quantities of tumor DNA in the bloodstream. These advancements have not only enhanced the sensitivity and specificity of liquid biopsies but have also broadened their potential applications, including early detection, prognosis, and monitoring of therapeutic efficacy and resistance. The continuous improvements in genomic technologies underscore their role in the growing adoption of liquid biopsies in clinical settings.

Growing Demand for Non-Invasive Procedures

The increasing preference for non-invasive diagnostic procedures among both patients and healthcare providers is another significant driver for the breast cancer liquid biopsy market. Traditional tissue biopsies, while effective, are invasive and often lead to discomfort and potential complications. In contrast, liquid biopsies offer a minimally invasive alternative that can be performed with a simple blood draw, reducing patient stress and risk. This patient-friendly approach is particularly advantageous for repeated testing required in monitoring tumor progression and response to treatment, making liquid biopsies an attractive option for continuous disease management.

Rising Prevalence of Breast Cancer

The rising global prevalence of breast cancer significantly fuels the demand for effective diagnostic and monitoring tools, boosting the liquid biopsy market. With breast cancer being one of the most common cancers worldwide, there is an urgent need for advancements in diagnostic techniques that can lead to earlier detection and improved patient outcomes. Liquid biopsies meet this need by providing a tool that can detect cancer at its earliest stages from a blood sample, facilitating timely intervention and personalized treatment plans. The increasing incidence of breast cancer globally is a compelling driver for the development and adoption of liquid biopsy solutions.

Restraint

Regulatory and Reimbursement Challenges

Despite the potential and growth of the breast cancer liquid biopsy market, it faces significant restraints with regulatory and reimbursement challenges. The novelty and complexity of liquid biopsy tests pose hurdles in gaining regulatory approvals from bodies like the FDA, as these agencies require extensive validation of the tests' clinical utility and accuracy before they can be broadly implemented. Furthermore, the lack of standardized guidelines for the use and interpretation of liquid biopsies adds to the regulatory challenges. On the reimbursement front, insufficient coverage and unclear reimbursement policies for liquid biopsies can deter healthcare providers from adopting this technology, as the financial costs of these advanced tests are often higher than traditional methods. These regulatory and reimbursement issues are substantial obstacles that slow the market's growth and widespread adoption.

Market Segmentation by Biomarkers

The breast cancer liquid biopsy market is segmented by biomarkers, including Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Exosomes, and Other Biomarkers. Among these, cfDNA leads in revenue generation due to its high clinical utility in detecting and monitoring minimal residual disease and treatment resistance. Its ability to provide rapid, non-invasive insights into tumor genetics makes cfDNA a preferred choice in clinical settings. Furthermore, cfDNA is projected to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period, driven by continuous advancements in sequencing technologies and increasing clinical adoption. On the other hand, CTCs also play a crucial role, particularly in understanding metastatic processes, though they capture a smaller portion of the market due to the technical challenges associated with their isolation and analysis. Exosomes are gaining traction as they provide comprehensive molecular information that potentially offers insights into tumor behavior and response to therapy. The segment of Other Biomarkers, which includes proteins and metabolites, shows promise due to ongoing research and potential to complement existing biomarkers for a more detailed disease profiling and treatment efficacy evaluation.

Market Segmentation by Products & Services

In the breast cancer liquid biopsy market, segmentation by Products & Services includes Kits & Reagents and Services. Kits & Reagents dominate in terms of revenue, as they are the foundational components used in liquid biopsy tests. This segment benefits from the frequent consumption and recurring purchases associated with liquid biopsy procedures, which involve multiple stages of testing over a patient's treatment course. Additionally, the ongoing innovation in reagents and kits, aimed at enhancing accuracy and efficiency, supports their high revenue generation. Meanwhile, Services are expected to witness the highest CAGR. This growth is fueled by the increasing preference for comprehensive service offerings that include test execution, data analysis, and actionable insights, which are highly valued in clinical settings for making informed treatment decisions. The rise in specialized diagnostic services and the expansion of laboratory capabilities to accommodate advanced liquid biopsy technologies contribute significantly to the growth of this segment.

Geographic Trends

The breast cancer liquid biopsy market demonstrates dynamic geographic trends, with North America currently leading in terms of revenue due to its advanced healthcare infrastructure, high awareness about cancer screenings, and the presence of key market players. However, Asia-Pacific is expected to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2032, driven by rising healthcare expenditures, increasing patient awareness, and improving healthcare facilities. The growing prevalence of breast cancer in countries like China and India, coupled with increasing investments in healthcare technologies, fuels the rapid growth in this region. Europe also maintains a significant share in the market, supported by its strong regulatory frameworks for cancer diagnostics and substantial healthcare spending.

Competitive Trends

In terms of competitive trends, the market sees robust participation from companies like Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience. These entities have leveraged various strategies to solidify their market positions and expand their revenue streams. In 2022, these companies reported substantial revenues, reflecting their dominance and innovative capabilities within the market. Their strategies for the forecast period of 2024 to 2032 are expected to focus on technological innovations, mergers and acquisitions, and geographic expansion. For instance, many of these firms are enhancing their product lines with integrations of advanced genomic technologies to increase the accuracy and reliability of liquid biopsies. Partnerships and collaborations are also crucial as companies aim to expand their global footprints, particularly in untapped markets within Asia-Pacific and Latin America. Moreover, investment in research and development is a key strategy for these companies, aiming to lead in the discovery of novel biomarkers and improve the sensitivity of existing liquid biopsy techniques. These strategic efforts are anticipated to drive the continued growth and competitive edge of these companies in the upcoming years, aligning with the overall expansion trends seen across the global market.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Breast Cancer Liquid Biopsy market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Breast Cancer Liquid Biopsy market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Biomarkers
    • Circulating tumor cells (CTCs)
    • Cell-free DNA (cfDNA)
    • Exosomes
    • Other biomarkers
  • Products & Services
    • Kits & reagents
    • Services
  • Sample Type
    • Blood
    • Urine
    • Other sample types
  • End Use
    • Hospitals
    • Cancer research centers
    • Diagnostic centers
    • Academic and research institutes
  • Region Segment (2022-2032; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Liquid Biopsy market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Breast Cancer Liquid Biopsy market?
  • Which is the largest regional market for Breast Cancer Liquid Biopsy market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Breast Cancer Liquid Biopsy market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Liquid Biopsy market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
  • 2.2. Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 (US$ Million)
  • 2.3. Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 (US$ Million)
  • 2.4. Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 (US$ Million)
  • 2.5. Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 (US$ Million)
  • 2.6. Global Breast Cancer Liquid Biopsy Market, By Geography, 2023 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2023

3. Breast Cancer Liquid Biopsy Market: Competitive Analysis

  • 3.1. Market Positioning of Key Breast Cancer Liquid Biopsy Market Vendors
  • 3.2. Strategies Adopted by Breast Cancer Liquid Biopsy Market Vendors
  • 3.3. Key Industry Strategies

4. Breast Cancer Liquid Biopsy Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Breast Cancer Liquid Biopsy Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Circulating tumor cells (CTCs)
    • 5.3.2. Cell-free DNA (cfDNA)
    • 5.3.3. Exosomes
    • 5.3.4. Other biomarkers

6. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Kits & reagents
    • 6.3.2. Services

7. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Blood
    • 7.3.2. Urine
    • 7.3.3. Other sample types

8. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 8.3. Market Segmentation
    • 8.3.1. Hospitals
    • 8.3.2. Cancer research centers
    • 8.3.3. Diagnostic centers
    • 8.3.4. Academic and research institutes

9. North America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 9.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 9.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 9.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 9.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 9.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 9.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 9.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

10. UK and European Union Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 10.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 10.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 10.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 10.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 10.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 10.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 10.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

11. Asia Pacific Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 11.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 11.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 11.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 11.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 11.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 11.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 11.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

12. Latin America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 12.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 12.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 12.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 12.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 12.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 12.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 12.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

13. Middle East and Africa Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
  • 13.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
  • 13.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
  • 13.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
  • 13.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
        • 13.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
        • 13.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
        • 13.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)

14. Company Profile

  • 14.1. Datar Cancer Genetics
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. Epic Sciences
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. F. Hoffmann-La Roche
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Genes2me
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. Illumina
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Menarini Silicon Biosystems
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. Myriad Genetics
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. OncoDNA
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. QIAGEN
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Sysmex
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. System Biosciences
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. Thermo Fisher Scientific
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. Twist Bioscience
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
  • 14.14. Other Notable Players
    • 14.14.1. Company Overview
    • 14.14.2. Financial Performance
    • 14.14.3. Product Portfolio
    • 14.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 2 Global Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 3 Global Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 4 Global Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 5 North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 6 North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 7 North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 8 North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 9 U.S. Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 10 U.S. Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 11 U.S. Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 12 U.S. Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 13 Canada Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 14 Canada Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 15 Canada Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 16 Canada Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 17 Rest of North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 18 Rest of North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 19 Rest of North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 20 Rest of North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 21 UK and European Union Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 22 UK and European Union Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 23 UK and European Union Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 24 UK and European Union Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 25 UK Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 26 UK Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 27 UK Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 28 UK Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 29 Germany Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 30 Germany Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 31 Germany Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 32 Germany Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 33 Spain Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 34 Spain Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 35 Spain Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 36 Spain Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 37 Italy Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 38 Italy Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 39 Italy Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 40 Italy Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 41 France Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 42 France Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 43 France Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 44 France Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 45 Rest of Europe Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 46 Rest of Europe Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 47 Rest of Europe Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 48 Rest of Europe Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 49 Asia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 50 Asia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 51 Asia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 52 Asia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 53 China Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 54 China Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 55 China Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 56 China Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 57 Japan Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 58 Japan Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 59 Japan Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 60 Japan Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 61 India Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 62 India Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 63 India Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 64 India Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 65 Australia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 66 Australia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 67 Australia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 68 Australia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 69 South Korea Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 70 South Korea Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 71 South Korea Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 72 South Korea Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 73 Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 74 Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 75 Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 76 Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 77 Brazil Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 78 Brazil Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 79 Brazil Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 80 Brazil Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 81 Mexico Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 82 Mexico Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 83 Mexico Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 84 Mexico Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 85 Rest of Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 86 Rest of Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 87 Rest of Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 88 Rest of Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 89 Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 90 Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 91 Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 92 Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 93 GCC Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 94 GCC Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 95 GCC Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 96 GCC Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 97 Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 98 Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 99 Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 100 Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
  • TABLE 101 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
  • TABLE 103 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
  • TABLE 104 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Breast Cancer Liquid Biopsy Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Breast Cancer Liquid Biopsy Market: Quality Assurance
  • FIG. 5 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023
  • FIG. 6 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023
  • FIG. 7 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023
  • FIG. 8 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023
  • FIG. 9 Global Breast Cancer Liquid Biopsy Market, By Geography, 2023
  • FIG. 10 Market Geographical Opportunity Matrix - Global Breast Cancer Liquid Biopsy Market, 2023
  • FIG. 11Market Positioning of Key Breast Cancer Liquid Biopsy Market Players, 2023
  • FIG. 12Global Breast Cancer Liquid Biopsy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
  • FIG. 13 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 Vs 2032, %
  • FIG. 14 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 Vs 2032, %
  • FIG. 15 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 Vs 2032, %
  • FIG. 16 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 Vs 2032, %
  • FIG. 17 U.S. Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 18 Canada Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 19 Rest of North America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 20 UK Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 21 Germany Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 22 Spain Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 23 Italy Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 24 France Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 25 Rest of Europe Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 26 China Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 27 Japan Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 28 India Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 29 Australia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 30 South Korea Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 31 Rest of Asia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 32 Brazil Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 33 Mexico Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 34 Rest of Latin America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 35 GCC Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 36 Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
  • FIG. 37 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032